Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)

被引：0

作者：

Grunwald, Viktor ^{[1
,2
]}

Powles, Thomas ^{[3
,4
]}

Eto, Masatoshi ^{[5
]}

Kopyltsov, Evgeny ^{[6
]}

Rha, Sun Young ^{[7
]}

Porta, Camillo ^{[8
]}

Motzer, Robert ^{[9
]}

Hutson, Thomas E. ^{[10
]}

Mendez-Vidal, Maria Jose ^{[11
]}

Hong, Sung-Hoo ^{[12
]}

Winquist, Eric ^{[13
]}

Goh, Jeffrey C. ^{[14
,15
]}

Maroto, Pablo ^{[16
]}

Buchler, Tomas ^{[17
,18
]}

Takagi, Toshio ^{[19
]}

Burgents, Joseph E. ^{[20
]}

Perini, Rodolfo ^{[21
]}

He, Cixin ^{[22
]}

Okpara, Chinyere E. ^{[23
]}

McKenzie, Jodi ^{[24
]}

Choueiri, Toni K. ^{[25
]}

机构：

[1] Univ Hosp Essen, Clin Med Oncol, Essen, Germany

[2] Univ Hosp Essen, Clin Urol, Essen, Germany

[3] Queen Mary Univ London, Barts Canc Inst, London, England

[4] Queen Mary Univ London, Royal Free Hosp, London, England

[5] Kyushu Univ, Dept Urol, Fukuoka, Japan

[6] State Inst Healthcare Reg Clin Oncol Dispensary, Omsk, Russia

[7] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea

[8] Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Bari, Italy

[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[10] Texas Oncol, Med Oncol, Dallas, TX USA

[11] Hosp Univ Reina Sofia, Dept Oncol, Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain

[12] Catholic Univ Korea, Seoul St Marys Hosp, Dept Urol, Seoul, South Korea

[13] Univ Western Ontario, Dept Oncol, London, ON, Canada

[14] ICON Res, South Brisbane, Qld, Australia

[15] Univ Queensland, St Lucia, Qld, Australia

[16] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

[17] Charles Univ Prague, Dept Oncol, Prague, Czech Republic

[18] Thomayer Univ Hosp, Prague, Czech Republic

[19] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan

[20] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA

[21] Merck & Co Inc, Clin Res, Rahway, NJ USA

[22] Eisai Inc, Biostat, Nutley, NJ USA

[23] Eisai Ltd, Clin Res, Hatfield, England

[24] Eisai Inc, Clin Res, Nutley, NJ USA

[25] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 13卷

关键词：

renal cell carcinoma; lenvatinib; pembrolizumab; sunitinib; bone metastases; liver metastases; lung metastases; sarcomatoid histology;

D O I：

10.3389/fonc.2023.1343027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[31] Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61) a single-arm, multicentre, phase 2 trial
Albiges, Laurence
Gurney, Howard
Atduev, Vagif
Suarez, Cristina
Climent, Miguel A.
Pook, David
Tomczak, Piotr
Barthelemy, Philippe
Lee, Jae Lyun
Stus, Viktor
Ferguson, Thomas
Wiechno, Pawel
Gokmen, Erhan
Lacombe, Louis
Gedye, Craig
Perini, Rodolfo F.
Sharma, Manish
Peng, Xiang
Lee, Chung-Han
LANCET ONCOLOGY, 2023, 24 (08) : 881 - 891
[32] Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
Zakharia, Yousef
Thomaidou, Despina
Li, Benjamin
Siu, Gordon
Levin, Rebecca
Vlahiotis, Anna
Rao, Dharanija
Zanotti, Giovanni
FRONTIERS IN ONCOLOGY, 2022, 12
[33] Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
Choueiri, Toni K.
McDermott, David F.
Merchan, Jaime
Bauer, Todd M.
Figlin, Robert
Heath, Elisabeth, I
Michaelson, M. Dror
Arrowsmith, Edward
D'Souza, Anishka
Zhao, Song
Roy, Ananya
Perini, Rodolfo
Vickery, Donna
Tykodi, Scott S.
LANCET ONCOLOGY, 2023, 24 (05) : 553 - 562
[34] Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
Carlo, Maria I.
Attalla, Kyrollis
Mazaheri, Yousef
Gupta, Sounak
Yildirim, Onur
Murray, Samuel J.
Coskey, Devyn T.
Kotecha, Ritesh
Lee, Chung-Han
Feldman, Darren R.
Russo, Paul
Patil, Sujata
Motzer, Robert J.
Coleman, Jonathan A.
Durack, Jeremy C.
Chen, Ying-Bei
Akin, Oguz
Ari Hakimi, A.
Voss, Martin H.
EUROPEAN UROLOGY, 2022, 81 (06) : 570 - 573
[35] Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial
Bilen, Mehmet Asim
Zurita, Amado J.
Ilias-Khan, Nasreen A.
Chen, Hsiang-Chun
Wang, Xuemei
Kearney, Alper Y.
Hodges, Sherie
Jonasch, Eric
Huang, Shixia
Khakoo, Aarif Yusuf
Tannir, Nizar M.
ONCOLOGIST, 2015, 20 (10) : 1140 - 1148
[36] Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma
Tannir, Nizar M.
Powles, Thomas
Escudier, Bernard
Donskov, Frede
Gruenwald, Viktor
Sternberg, Cora N.
Schmidinger, Manuela
Schoeffski, Patrick
Szczylik, Cezary
Peltolta, Katriina
Nosov, Dmitry
Melichar, Bohuslav
Clary, Douglas
Scheffold, Christian
Motzer, Robert J.
Choueiri, Toni K.
KIDNEY CANCER, 2020, 4 (01) : 29 - 39
[37] STELLAR-304: a phase III study of zanzalintinib (XL092) plus nivolumab in advanced non-clear cell renal cell carcinoma
Pal, Sumanta K.
Powles, Thomas
Kanesvaran, Ravindran
Molina-Cerrillo, Javier
Feldman, Darren R.
Barata, Pedro
Liu, Mohan
Bhatt, Aarohi
Wang, Zhong
Nandoskar, Prachi
Suarez, Cristina
FUTURE ONCOLOGY, 2025, 21 (07) : 787 - 794
[38] Final database lock results of the phase 2 cohort of lenvatinib plus pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma
Lee, Chung-Han
Shah, Amishi Yogesh
Rao, Arpit
Taylor, Matthew H.
Pinto, Alvaro
Sarrio, Regina Girones
Cohn, Allen Lee
Bilen, Mehmet Asim
Ribe, Sara Gunnestad
Goksel, Musaberk
Tennoe, Oyvind Krohn
Richards, Donald
Sweis, Randy F.
Heinrich, Daniel
Perini, Rodolfo
Kubiak, Peter
Huang, Jie
Motzer, Robert J.
ONCOLOGIST, 2023, 28 : S3 - +
[39] Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial
Tykodi, Scott S.
Gordan, Lucio N.
Alter, Robert S.
Arrowsmith, Edward
Harrison, Michael R.
Percent, Ivor
Singal, Rakesh
Van Veldhuizen, Peter
George, Daniel J.
Hutson, Thomas
Zhang, Joshua
Zoco, Jesus
Johansen, Jennifer L.
Kalebasty, Arash Rezazadeh
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (02)
[40] A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)
Lara Jr, Primo N.
Villanueva, Luis
Ibanez, Carolina
Erman, Mustafa
Lee, Jae Lyun
Heinrich, Daniel
Lipatov, Oleg Nikolaevich
Gedye, Craig
Gokmen, Erhan
Acevedo, Alejandro
Semenov, Andrey
Park, Se Hoon
Gafanov, Rustem Airatovich
Kose, Fatih
Jones, Mark
Du, Xiaoqi
Munteanu, Mihaela
Perini, Rodolfo
Choueiri, Toni K.
Motzer, Robert J.
BMC CANCER, 2024, 23 (SUPPL 1)

← 1 2 3 4 5 →